I agree that Acadia would want protection from NNZ-2591 competing against its Daybue product for Rett. This was achieved via the exclusive licence being given to it. My point is that an evident payment should have been received for that protection, as is normal.
Why protection for Fragile-X was included in the licence also, with no competing Acadia product in the market or in development, is not as obvious.
As you suggest, a free licence may have been employed as a component in negotiations for the trofinetide ROW agreement. If so, Neuren could have received indirect benefit in this way.
Cheers
NEU Price at posting:
$10.53 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)